FMR LLC and Abigail P. Johnson filed a Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of approximately 6.4% of the common stock of Tarsus Pharmaceuticals Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each reported beneficial ownership of 3,143,158.20 shares of Tarsus Pharmaceuticals common stock.
  • Percent of class: The reported holdings represent 6.4% of the outstanding common stock, according to the filing.
  • Sole voting power (FMR LLC): FMR LLC reported sole voting power over 3,139,690.00 shares, with no shared voting power.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson each reported sole dispositive power over 3,143,158.20 shares, with no shared dispositive power.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Ordinary course certification: The filing certifies that the securities "were acquired and are held in the ordinary course of business" and not for the purpose of changing or influencing control of the issuer.

FMR LLC and Abigail P. Johnson Disclose Position in Tarsus Pharmaceuticals Common Stock

According to the Schedule 13G filed on November 4, 2026, FMR LLC, a Delaware-organized holding company located at 245 Summer Street, Boston, Massachusetts 02210, reported aggregate beneficial ownership of 3,143,158.20 shares of common stock of Tarsus Pharmaceuticals Inc. (CUSIP 87650L103). The filing identifies Tarsus Pharmaceuticals Inc. as headquartered at 15440 Laguna Canyon Road, Irvine, CA 92618. FMR LLC is classified as a parent holding company or control person for purposes of the filing.

Abigail P. Johnson, a United States citizen, is also named as a reporting person with the same aggregate beneficial ownership figure of 3,143,158.20 shares, representing 6.4% of the class. The filing discloses that Johnson holds sole dispositive power over those shares but reported zero sole or shared voting power. FMR LLC, by contrast, reported sole voting power over 3,139,690.00 shares. Neither reporting person reported any shared voting or shared dispositive power.

The filing notes under Item 6 that "one or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TARSUS PHARMACEUTICALS INC," but specifies that no single other person's interest exceeds five percent of the total outstanding common stock. The filing was signed by Stephanie J. Brown under a power of attorney on behalf of both FMR LLC and Abigail P. Johnson. Subsidiary identification information is provided in Exhibit 99 attached to the filing.

What Was Disclosed

FMR LLC and Abigail P. Johnson filed a Schedule 13G reporting combined beneficial ownership of 3,143,158.20 shares, or 6.4%, of Tarsus Pharmaceuticals Inc. common stock as of September 30, 2026, with the filing submitted November 4, 2026.